New Dual-Targeting CAR t therapy shows promise in early lymphoma trial
NCT ID NCT05169489
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 26 times
Summary
This early-phase study tested a new treatment called bbT369 for people with B cell non-Hodgkin's lymphoma that came back or didn't respond to standard therapy. The treatment uses a patient's own immune cells, modified to target two markers on cancer cells, plus a gene edit to improve effectiveness. The trial was terminated early, but results may still inform future research.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Colorado Blood Cancer Institute
Denver, Colorado, 80218, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
Sarah Cannon
Nashville, Tennessee, 37203, United States
-
Stanford Cancer Institute
Stanford, California, 94305, United States
Conditions
Explore the condition pages connected to this study.